---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-024098"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:28:41.617251+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protara Therapeutics Q1 2022 net loss narrows to $10.8M; cash $118.5M funds into mid-2024

## Summary
- Net loss of $10.8M ($0.96/share) versus $13.5M ($1.20/share) in Q1 2021.
- Cash and equivalents $118.5M as of March 31, 2022; expected to fund operations into mid-2024.
- Phase 1 ADVANCED-1 trial of TARA-002 for NMIBC first patient dosed in March 2022.
- FDA preliminary guidance received for TARA-002 in lymphatic malformations; Phase 2 trial planning underway.
- U.S. patent issued for IV Choline Chloride composition with term expiring in 2041.

## SEC filing metadata
- accession: 0001213900-22-024098
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390022024098/0001213900-22-024098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390022024098/ea159335-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-024098
- JSON: https://secwatch.observer/filing/0001213900-22-024098.json
- Plain text: https://secwatch.observer/filing/0001213900-22-024098.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.